Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Adamis Pharmaceuticals Co. stock logo
ADMP
Adamis Pharmaceuticals
$1.28
$0.75
$26.18
$7.26M1.27811,695 shs119,800 shs
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
$5.88
+1.9%
$6.16
$4.92
$9.30
$3.16M1.0323,368 shs9,045 shs
Revelation Biosciences, Inc. stock logo
REVB
Revelation Biosciences
$0.77
+3.8%
$2.15
$0.73
$60.80
$720K-0.09364,780 shs304,871 shs
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
$2.94
-3.3%
$3.20
$1.75
$9.37
$4.99M1.38805,258 shs15,663 shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Adamis Pharmaceuticals Co. stock logo
ADMP
Adamis Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
-0.44%-8.55%+2.87%+0.92%-24.03%
Revelation Biosciences, Inc. stock logo
REVB
Revelation Biosciences
+3.75%-3.52%-68.15%-73.13%-97.71%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
-3.29%-4.55%-8.41%-9.54%+1,357.61%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Adamis Pharmaceuticals Co. stock logo
ADMP
Adamis Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
2.424 of 5 stars
3.64.00.00.00.00.00.6
Revelation Biosciences, Inc. stock logo
REVB
Revelation Biosciences
0.2411 of 5 stars
0.02.00.00.00.60.01.3
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
0.3579 of 5 stars
0.03.00.00.02.80.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Adamis Pharmaceuticals Co. stock logo
ADMP
Adamis Pharmaceuticals
0.00
N/AN/AN/A
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
3.20
Buy$33.00461.22% Upside
Revelation Biosciences, Inc. stock logo
REVB
Revelation Biosciences
0.00
N/AN/AN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest ARTL, REVB, ADMP, and SNOA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/11/2025
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
D Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
6/6/2025
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$36.00
4/28/2025
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$36.00 ➝ $36.00
4/2/2025
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$36.00 ➝ $36.00
(Data available from 6/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Adamis Pharmaceuticals Co. stock logo
ADMP
Adamis Pharmaceuticals
$4.76M0.00N/AN/A($1.26) per share0.00
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
N/AN/AN/AN/A$5.31 per shareN/A
Revelation Biosciences, Inc. stock logo
REVB
Revelation Biosciences
N/AN/AN/AN/A$9.02 per shareN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
$14.29M0.34N/AN/A$2.73 per share1.08
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Adamis Pharmaceuticals Co. stock logo
ADMP
Adamis Pharmaceuticals
-$26.48MN/A0.00N/AN/A-502.73%-420.53%-256.87%N/A
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
-$9.83M-$17.94N/AN/AN/AN/A-226.99%-164.61%8/12/2025 (Estimated)
Revelation Biosciences, Inc. stock logo
REVB
Revelation Biosciences
-$15.04M-$102.61N/AN/AN/AN/A-299.46%-115.36%8/8/2025 (Estimated)
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
-$3.46M-$3.10N/AN/AN/A-24.23%-58.73%-21.05%8/6/2025 (Estimated)

Latest ARTL, REVB, ADMP, and SNOA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
6/17/2025Q4 2025
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
-$0.73-$0.15+$0.58-$0.48$4.44 million$3.75 million
5/13/2025Q1 2025
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
-$0.78-$4.32-$3.54-$0.72N/AN/A
5/8/2025Q1 2025
Revelation Biosciences, Inc. stock logo
REVB
Revelation Biosciences
-$6.88-$2.11+$4.77-$2.11N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Adamis Pharmaceuticals Co. stock logo
ADMP
Adamis Pharmaceuticals
N/AN/AN/AN/AN/A
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
N/AN/AN/AN/AN/A
Revelation Biosciences, Inc. stock logo
REVB
Revelation Biosciences
N/AN/AN/AN/AN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Adamis Pharmaceuticals Co. stock logo
ADMP
Adamis Pharmaceuticals
N/A
0.23
0.19
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
N/A
0.49
0.49
Revelation Biosciences, Inc. stock logo
REVB
Revelation Biosciences
N/A
3.60
3.60
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
N/A
3.09
2.38

Institutional Ownership

CompanyInstitutional Ownership
Adamis Pharmaceuticals Co. stock logo
ADMP
Adamis Pharmaceuticals
38.55%
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
0.87%
Revelation Biosciences, Inc. stock logo
REVB
Revelation Biosciences
12.80%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
1.95%
CompanyEmployeesShares OutstandingFree FloatOptionable
Adamis Pharmaceuticals Co. stock logo
ADMP
Adamis Pharmaceuticals
119.36 million9.24 millionOptionable
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
5550,000542,000Not Optionable
Revelation Biosciences, Inc. stock logo
REVB
Revelation Biosciences
10960,000942,000Not Optionable
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
1801.64 million1.58 millionNot Optionable

Recent News About These Companies

Sonoma Pharmaceuticals expands into UK market
Sonoma Pharmaceuticals, Inc. (O8Z.F)
Sonoma Pharmaceuticals announces relaunch of dermatology, eye care lines

New MarketBeat Followers Over Time

Media Sentiment Over Time

Adamis Pharmaceuticals stock logo

Adamis Pharmaceuticals NASDAQ:ADMP

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease. Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose. The company is headquartered in San Diego, California.

Artelo Biosciences stock logo

Artelo Biosciences NASDAQ:ARTL

$5.88 +0.11 (+1.91%)
Closing price 06/23/2025 03:47 PM Eastern
Extended Trading
$5.88 0.00 (0.00%)
As of 06/23/2025 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.

Revelation Biosciences stock logo

Revelation Biosciences NASDAQ:REVB

$0.77 +0.03 (+3.75%)
Closing price 06/23/2025 04:00 PM Eastern
Extended Trading
$0.74 -0.03 (-4.39%)
As of 06:20 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was founded in 2020 and is based in San Diego, California.

Sonoma Pharmaceuticals stock logo

Sonoma Pharmaceuticals NASDAQ:SNOA

$2.94 -0.10 (-3.29%)
Closing price 06/23/2025 04:00 PM Eastern
Extended Trading
$2.95 +0.01 (+0.34%)
As of 06:37 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Gramaderm for the treatment of topical mild to moderate acne; Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens; Ocucyn eyelid and eyelash cleanser; Microdacyn60 oral care solution for the treatment of mouth and throat infections; and Podiacyn, a foot care product. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; MicrocynVS, a veterinarian-strength animal care product used in vet clinics and animal hospitals; Nanocyn, a hospital-grade disinfectant; Acuicyn, an antimicrobial prescription solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; and Sinudox for nasal irrigation. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.